Rahul Jandial, M.D., Ph.D.: Pediatric Neurosurgery Humanitarian Missions

March 13, 2018 | Denise Heady

Fourteen years ago, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., began to travel to underserved countries to perform brain surgeries on disadvantaged children.

Continue Reading

Promising Sickle Cell Research Gets Nearly $6MM Boost from CIRM

March 22, 2018 | Michael Easterling

Thanks to a $5.74 million award from the California Institute for Regenerative Medicine, City of Hope’s Joseph Rosenthal, M.D., and his team can advance their research into finding a cure for sickle cell disease.

New Clues Could Point to Better Treatments for Chronic Graft-Versus-Host Disease (GVHD)

November 9, 2017 | By Katie Neith

City of Hope’s Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation and colleagues recently uncovered important information about the chronic GVHD.

Novel Treatment May Stop Graft-Versus-Host Disease

April 18, 2017 | Katie Neith

An international team of researchers led by City of Hope’s Defu Zeng believe they may have found a way to prevent graft-versus host disease following stem cell transplants without sacrificing the transplants’ ability to fight leukemia and lymphoma.

Patient's 17-year battle with rare blood cancer won’t dim her spirit

January 12, 2016 | Letisia Marquez

Cheryl Taylor spent New Year’s Day in a brand new way. The City of Hope patient watched the Rose Parade from the grandstands, surrounded by strangers who quickly became friends after she told them she’s battled a rare, debilitating blood cancer – a myeloproliferative neoplasm – for almost 17 years.

$2.2 million grant will benefit graft-versus-host disease research

November 20, 2015 | City of Hope

Graft-versus-host disease is a serious condition that affects many people who receive a bone marrow cell transplant. To better fight it, scientists need to better understand it. City of Hope researchers’ efforts to do just that recently got a $2.2 million boost from the National Institute of Allergy and Infectious Diseases, also known as NIAID.

Meet our doctors: Jonathan Cotliar on graft-versus-host disease

February 20, 2015 | Kim Proescholdt

Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor's stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 percent of patients.

A better treatment for graft-versus-host disease? It's possible

February 9, 2015 | Darrin Joy

Cancer patients face a daunting journey marked by challenges and uncertainties. For those undergoing bone marrow, or stem cell, transplantation, one complication poses a particular threat — chronic graft-versus-host disease (GVHD).